Mourad W A, Devloo S, Setrakian S
Departments of Pathology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, and University of Alberta, Edmonton, Canada, and Fairview General Hospital, Cleveland, Ohio, United States.
Ann Saudi Med. 1997 Jul;17(4):427-31. doi: 10.5144/0256-4947.1997.427.
Ductal carcinoma in situ (DCIS) of the breast shows unpredictable association with invasive ductal carcinoma (IDC). Comedo DCIS (CDCIS) is more frequently associated with IDC than noncomedo DCIS (NCDCIS). We studied prognostic variables in 64 cases of DCIS to identify predictors of invasion. These factors included DCIS type and nuclear grade and two counts of the AgNOR silver staining technique for identification of ploidy and proliferative activity (PA) using two counts: mAgNOR for ploidy and pAgNOR for PA. The other factors included immunostaining of the lesions for epidermal growth factor receptors (EGFR), cathepsin-D (C-D), and the c-erbB-2 oncogene. The 34 cases associated with ICD had pAgNOR ranging from 3% to 36% (median 11%), whereas cases not associated with IDC had a pAgNOR range of 0% to 25% (median 5%; P=0.0001). The correlation between mAgNOR and the development of IDC was less statistically significant. The DCIS type and staining pattern for EGFR, C-D, and c-erbB-2 showed no statistical correlation of individual variables with the development of IDC. A scoring system adding the values of the seven variables was used. A score of 1-2 was given to each variable, depending on whether it was positive or negative. Lesions associated with IDC had a median total score of 8 (+/- 1.35 SD), whereas those lesions not associated with invasion had a median score of 4 (+/- 1.45 SD; P=0.0002). We conclude that proliferative activity analysis may play a significant role in predicting the invasive potential of DCIS. The use of a scoring system adding the sum of single prognostic indicators may provide more useful information regarding the prediction of invasive potential of DCIS than single indicators.
乳腺导管原位癌(DCIS)与浸润性导管癌(IDC)之间的关联难以预测。粉刺型DCIS(CDCIS)比非粉刺型DCIS(NCDCIS)更常与IDC相关。我们研究了64例DCIS的预后变量,以确定侵袭的预测因素。这些因素包括DCIS类型和核分级,以及通过两种计数的AgNOR银染色技术来识别倍性和增殖活性(PA):用于倍性的mAgNOR和用于PA的pAgNOR。其他因素包括病变的表皮生长因子受体(EGFR)、组织蛋白酶-D(C-D)和c-erbB-2癌基因的免疫染色。与浸润性癌相关的34例病例的pAgNOR范围为3%至36%(中位数为11%),而与IDC不相关的病例的pAgNOR范围为0%至25%(中位数为5%;P=0.0001)。mAgNOR与IDC发生之间的相关性在统计学上不太显著。DCIS类型以及EGFR、C-D和c-erbB-2的染色模式显示,各个变量与IDC发生之间无统计学相关性。使用了一个将七个变量的值相加的评分系统。根据每个变量是阳性还是阴性,给其打1至2分。与IDC相关的病变的总得分中位数为8(±1.35标准差),而那些与浸润无关的病变的得分中位数为4(±1.45标准差;P=0.0002)。我们得出结论,增殖活性分析可能在预测DCIS的侵袭潜能方面发挥重要作用。使用一个将单个预后指标相加的评分系统,可能比单个指标提供更多关于预测DCIS侵袭潜能的有用信息。